Exhaled breath temperature in asthma: Fig. 1.—

<h3>Background</h3> Transarterial chemoembolization (TACE) is the therapy which have chosen in 50-60% of patients with Hepatocellular carcinoma (HCC). Recently, Hepatoma Arterial Embolization (HAP) score stratifies patients who will benefit from the first TACE. We conducted a survey to investigate the value of HAP score in the prognosis of HCC treated with TACE in Vietnam. <h3>Methods</h3> Prospective cohort study in patients with HCC and first TACE at the Department of Internal Medicine, Hanoi Medical University Hospital, Vietnam, from January 2017 to June 2021. The HAP score (serum albumin 0.9 mg/dl, alpha-foetoprotein &gt;400 ng/ml, and tumor size &gt;7 cm), and ALBI score was applied before first TACE, mortality and survival were observed with a follow-up of 54 months. <h3>Results</h3> We included 106 patients with age of 62.8 ± 10.1 years. In this population, HCC risk factor was mainly hepatitis B with 75.5% (80/106). The HAP score classified 19, 41, 31 and 15 patients as HAP A, B, C and D, respectively, (IDDF2021-ABS-0070 Table 1). The median follow–up time was 37.5±1.2 months for HAP A, 40.8±2.9 months for HAP B, 24.0±2.5 months for HAP C and 20.4±4.1 months for HAP D. There were no deaths at the first year in HAP A. The cumulative proportion surviving at first years for HAP B, C, D was 97.4; 77.9 and 66.7, respectively. At 36 months, this percentage for HAP A, B, C and D was 92.3; 72.5; 31.1 and 27.1, respectively, (IDDF2021-ABS-0070 Table 2). Survival of all subgroups differed significantly from each other (each p &lt; 0.05) (IDDF2021-ABS-0070 Figure 2. Kaplan-Meier curve for HAP score). Area under the curve for receiver operating characteristic of HAP score was 0.71 and higher than this of ALBI grade (0.57) (IDDF2021-ABS-0070 Figure 3. ROC curves for HAP score and ALBI grade), indicating a significant performance of HAP score compared with ALBI grade in prognosis of HCC treated with TACE. <h3>Conclusions</h3> HAP is a useful score to assist for the management decisions of patients with HCC requiring TACE due to its value in predicting mortality and survival.